Filing Details

Accession Number:
0000950170-24-017091
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-20 16:05:46
Reporting Period:
2024-02-15
Accepted Time:
2024-02-20 16:05:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1654151 Deciphera Pharmaceuticals Inc. DCPH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1410514 Patrick Thomas Kelly C/O Deciphera Pharmaceuticals, Inc.
200 Smith Street
Waltham MA 02451
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-15 17,275 $0.00 83,360 No 4 A Direct
Common Stock Disposition 2024-02-16 3,010 $15.62 80,350 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-02-15 69,100 $0.00 69,100 $15.92
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
69,100 2034-02-14 No 4 A Direct
Footnotes
  1. The reporting person was awarded 17,275 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027.
  2. This sale was to cover tax liabilities in the vesting of RSUs.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6175 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024.